Lyell Immunopharma, Inc.
For the period ended Mar 12, 2026. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 12, 2026 · Filed Mar 12, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Statement of Operations Data:
Statement of Operations Data:
| Three Months Ended December 31, | Year Ended December 31, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue | $6 | $11 | $36 | $61 |
| Operating expenses: | ||||
| Research and development(1) | 52,199 | 48,668 | 158,675 | 171,603 |
| General and administrative | 10,616 | 14,522 | 45,135 | 52,041 |
| Other operating income, net | (1,497) | (513) | (2,145) | (3,309) |
| Acquired in-process research and development | 66,332 | 87,184 | 66,332 | 87,184 |
| Impairment of long-lived assets | — | 51,297 | 1,443 | 51,297 |
| Total operating expenses | 127,650 | 201,158 | 269,440 | 358,816 |
| Loss from operations | (127,644) | (201,147) | (269,404) | (358,755) |
| Interest income, net | 2,676 | 4,920 | 13,080 | 24,068 |
| Other (expense) income, net(1) | (15,755) | 4,292 | (18,124) | 4,694 |
| Impairment of other investments | — | — | — | (13,001) |
| Total other (loss) income, net | (13,079) | 9,212 | (5,044) | 15,761 |
| Net loss | $(140,723) | $(191,935) | $(274,448) | $(342,994) |
(1)As of October 1, 2024, the Company’s success payment liability was recognized at fair value as Stanford had provided the requisite service obligation to earn the potential success payment consideration. The change in the estimated fair value of Stanford success payment liabilities beginning in Q4 2024 was recognized within other (expense) income, net in the Consolidated Statements of Operations and Comprehensive Loss. The change in the estimated fair value of Stanford success payment liabilities in the first nine months of 2024 were recognized within research and development expenses in the Consolidated Statements of Operations and Comprehensive Loss. The change in the estimated fair value of Fred Hutch success payment liabilities was recognized within other (expense) income, net in the Consolidated Statements of Operations and Comprehensive Loss.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.